However, case series report efficacy of 21-day/cycle midostaurin + VEN in t(8;21)(q22;q22.1)/AML1-ETO) core binding factor-AML associated with KIT mutations, R/R to frontline HMA + VEN regimens [59]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.